Scholarlink

Background <p>Severe community-acquired pneumonia (sCAP) is a major contributor to global hospital mortality, with some patients rapidly progressing to death within a few days due to acute respiratory distress syndrome (ARDS), septic shock, or multiorgan failure (MOFS). Despite the significant health burden, these cases remain poorly defined, often overlooked in clinical practice, and insufficiently addressed in existing guidelines.</p> Methods <p>In this multicenter retrospective study, we analyzed 1,517 hospitalized patients with sCAP for assessing the incidence of fulminant pneumonia -defined as sCAP leading to death within 7 days from hospital admission- and to identify factors associated with either an increased or reduced risk of unfavorable outcome.</p> Results <p>Our findings revealed a 5.9% incidence of fulminant pneumonia, with early death primarily due to ARDS (93%), sepsis (70%), and MOFS (73%). Older age, obesity, diabetes, cardiovascular disease, and elevated serum creatinine were associated with increased risk, while early corticosteroid administration was associated with a significant mortality reduction within seven days, both in the univariate and multivariate analyses (OR 0.22, CI 95% 0.12–0.38, <i>p</i> &lt; 0.001). Baseline respiratory impairment and inflammatory markers were not associated with early mortality.</p> Conclusion <p>These findings highlight the importance of recognizing sCAP as a time-dependent condition, requiring early identification and treatment of cases at risk for developing fulminant pneumonia at hospital admission. Larger studies and randomized controlled trials are necessary to validate these findings and optimize treatment strategies.</p> Clinical trial registration <p>ClinicalTrials.gov NCT06516601.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Existence and relevance of fulminant severe community-acquired pneumonia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月5日

查看全文
  • Francesco Salton,
  • Jesús Villar,
  • Michele Mondoni,
  • Sergio Harari,
  • Andrea Salotti,
  • Alfonso Ambrós,
  • Francisco Alba,
  • Carlos Ferrando,
  • Tomàs Muñoz,
  • Juan A. Soler,
  • Lina Pérez-Méndez,
  • Cristina Férnandez,
  • Domingo Martinez,
  • Stefano Gasparotto,
  • Stefano Centanni,
  • Umberto Zuccon,
  • Giulia Barbati,
  • Andrea Rocca,
  • Barbara Ruaro,
  • Marco Confalonieri,
  • Paola Confalonieri

摘要

Background

Severe community-acquired pneumonia (sCAP) is a major contributor to global hospital mortality, with some patients rapidly progressing to death within a few days due to acute respiratory distress syndrome (ARDS), septic shock, or multiorgan failure (MOFS). Despite the significant health burden, these cases remain poorly defined, often overlooked in clinical practice, and insufficiently addressed in existing guidelines.

Methods

In this multicenter retrospective study, we analyzed 1,517 hospitalized patients with sCAP for assessing the incidence of fulminant pneumonia -defined as sCAP leading to death within 7 days from hospital admission- and to identify factors associated with either an increased or reduced risk of unfavorable outcome.

Results

Our findings revealed a 5.9% incidence of fulminant pneumonia, with early death primarily due to ARDS (93%), sepsis (70%), and MOFS (73%). Older age, obesity, diabetes, cardiovascular disease, and elevated serum creatinine were associated with increased risk, while early corticosteroid administration was associated with a significant mortality reduction within seven days, both in the univariate and multivariate analyses (OR 0.22, CI 95% 0.12–0.38, p < 0.001). Baseline respiratory impairment and inflammatory markers were not associated with early mortality.

Conclusion

These findings highlight the importance of recognizing sCAP as a time-dependent condition, requiring early identification and treatment of cases at risk for developing fulminant pneumonia at hospital admission. Larger studies and randomized controlled trials are necessary to validate these findings and optimize treatment strategies.

Clinical trial registration

ClinicalTrials.gov NCT06516601.